Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Influenza

First cell-based quadrivalent vaccine available for 2019/2020 flu season

The first cell-based quadrivalent influenza vaccine to be made available in Europe has now been licensed by the European Commission.

Older person recieving flu vaccine

Source: Shutterstock.com

Flucelvax Tetra (Sequiris), a cell-based seasonal influenza vaccine, has been issued marketing approval by the European Commission

A new cell-based seasonal influenza vaccine has been issued marketing approval by the European Commission and will be available for the 2019/2020 flu season.

Flucelvax® Tetra (Seqirus) is the first cell-based quadrivalent influenza vaccine (QIVc) to be made available in Europe and is licensed for use in individuals aged nine years and older.

To date, there have been no randomised controlled trials comparing the efficacy of QIVc and standard egg-based quadrivalent vaccines (QIVe), but in an analysis of more than 1.3 million medical records presented at the Canadian Immunisation Conference in December 2018, Seqirus highlighted that QIVc was more than 36% more effective than QIVe in preventing influenza-like illness in people aged four years and older during the 2017/2018 influenza season in the United States.

“This real-world study, along with other emerging evidence, indicates that cell-based influenza vaccines may result in better influenza-related outcomes compared to standard egg-based vaccine options in some seasons — particularly those seasons characterised by egg-adapted changes,” said Russell Basser, senior vice president of research and development at Seqirus.

“We are greatly encouraged by the data and look forward to working with academic partners to generate additional data in future seasons.”

In the UK, the potential advantages of QIVc, which is cultured in mammalian cells rather than eggs, have already been recognised in guidance issued by the Joint Committee on Vaccination and Immunisation (JCVI) for the 2019/2020 influenza season. JCVI advised that QIVc would be suitable for use in people aged 65 years and older, as well for use in at-risk groups aged under 65 years. 

“We are pleased to be bringing Flucelvax Tetra to the UK next season and have sufficient capacity at our cell-based manufacturing facility in the US to also ensure supply in September 2019, regardless of demand,” said Sharon McHale, head of corporate affairs at Seqirus.

“The JCVI has recommended it as one of the vaccine options for adults [aged] over 18 years in at risk groups and we expect the NHS to issue guidance on its reimbursement very soon.”

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2019.20206011

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Pharmacy Registration Assessment Questions 2

    Pharmacy Registration Assessment Questions 2

    Pharmacy Registration Assessment Questions 2 features more than 400 entirely new, closed book and calculation questions. It can be used in conjunction with the previous volume or on its own. All questions are in line with current GPhC guidance, enabling you to prepare for the pharmaceutical pre-registration exam with confidence.

    £35.00Buy now
  • Integrated Pharmacy Case Studies

    Integrated Pharmacy Case Studies

    Over 90 case studies based on real life patient-care scenarios. Each case includes learning outcomes and references.

    £47.00Buy now
  • Remington Education: Drug Information and Literature Evaluation

    Remington Education: Drug Information and Literature Evaluation

    Remington Education: Drug Information & Literature Evaluation teaches students how to effectively and efficiently locate and analyze up-to-date drug information and literature.

    £27.00Buy now
  • English Delftware Drug Jars

    English Delftware Drug Jars

    This beautiful book illustrates the art and history of the collection of English delftware drug jars in the Museum of the Royal Pharmaceutical Society of Great Britain.

    £54.00Buy now
  • Pharmacy OSCEs

    Pharmacy OSCEs

    The only pharmacy-specific OSCE revision guide. This easy-to-use book covers the key competencies that will be tested in your exams.

    £25.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.